Common brain malformation traced to its genetic roots – Washington University School of Medicine in St. Louis

Visit the News Hub

Discovery could aid early screening, shed light on how Chiari malformation arises

The lowest part of a child's brain is visible below the bottom of the skull in this MRI scan and shows evidence of a Chiari 1 malformation. Researchers at Washington University School of Medicine in St. Louis have shown that Chiari 1 malformation can be caused by variations in two genes linked to brain development, and that children with large heads are at increased risk of developing the condition.

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. But in about one in 10 of those children, the condition causes headaches, neck pain, hearing, vision and balance disturbances, or other neurological symptoms.

In some cases, the disorder may run in families, but scientists have understood little about the genetic alterations that contribute to the condition. In new research, scientists at Washington University School of Medicine in St. Louis have shown that Chiari 1 malformation can be caused by variations in two genes involved in brain development.

The condition occurs when the lowest parts of the brain are found below the base of the skull. The study also revealed that children with unusually large heads are four times more likely to be diagnosed with Chiari 1 malformation than their peers with normal head circumference.

The findings, published Dec. 21 in the American Journal of Human Genetics, could lead to new ways to identify people at risk of developing Chiari 1 malformation before the most serious symptoms arise. It also sheds light on the development of the common but poorly understood condition.

A lot of times people have recurrent headaches, but they dont realize a Chiari malformation is the cause of their headaches, said senior author Gabriel Haller, PhD, an assistant professor of neurosurgery, of neurology and of genetics. And even if they do, not everyone is willing to have brain surgery to fix it. We need better treatments, and the first step to better treatments is a better understanding of the underlying causes.

If people start experiencing severe symptoms like chronic headaches, pain, abnormal sensations or loss of sensation, or weakness, the malformation is treated with surgery to decompress the Chiari malformation.

Theres an increased risk for Chiari malformations within families, which suggests a genetic underpinning, but nobody had really identified a causal gene, Haller said. We were able to identify two causal genes, and we also discovered that people with Chiari have larger head circumference than expected. Its a significant factor, and easy to measure. If you have a child with an enlarged head, it might be worth checking with your pediatrician.

To identify genes that cause Chiari 1 malformation, Haller and colleagues sequenced all the genes of 668 people with the condition, as well as 232 of their relatives. Of these relatives, 76 also had Chiari 1 malformation and 156 were unaffected. The research team included first author Brooke Sadler, PhD, an instructor in pediatrics, and co-authors David D. Limbrick, Jr., MD, PhD, a professor of neurosurgery and director of the Division of Pediatric Neurosurgery, and Christina Gurnett, MD, PhD, a professor of neurologyand director of the Division of Pediatric and Developmental Neurology, among others.

Sequencing revealed that people with Chiari 1 malformation were significantly more likely to carry mutations in a family of genes known as chromodomain genes. Several of the mutations were de novo, meaning the mutation had occurred in the affected person during fetal development and was not present in his or her relatives. In particular, the chromodomain genes CHD3 and CHD8 included numerous variants associated with the malformation.

Further experiments in tiny, transparent zebrafish showed that the gene CHD8 is involved in regulating brain size. When the researchers inactivated one copy of the fishs chd8 gene, the animals developed unusually large brains, with no change in their overall body size.

Chromodomain genes help control access to long stretches of DNA, thereby regulating expression of whole sets of genes. Since appropriate gene expression is crucial for normal brain development, variations in chromodomain genes have been linked to neurodevelopmental conditions such as autism spectrum disorders, developmental delays, and unusually large or small heads.

Its not well known how chromodomain genes function since they have such a wide scope of activity and they are affecting so many things at once, Haller said. But they are very intriguing candidates for molecular studies, to understand how specific mutations lead to autism or developmental delay or, as in many of our Chiari patients, just to increased brain size without cognitive or intellectual symptoms. Wed like to figure out the effects of each of these mutations so that in the future, if we know a child has a specific mutation, well be able to predict whether that variant is going to have a harmful effect and what kind.

The association between chromodomain genes and head size inspired Haller and colleagues to measure the heads of children with Chiari malformations, comparing them to age-matched controls and to population averages provided by the Centers for Disease Control and Prevention. Children with Chiari tended to have larger than average heads. Those children with the largest heads bigger than 95% of children of the same age were four times more likely to be diagnosed with the malformation.

The findings suggest that children with larger heads or people with other neurodevelopmental disorders linked to chromodomain genes may benefit from screening for Chiari malformation.

A lot of kids that have autism or developmental disorders associated with chromodomain genes may have undiscovered Chiari malformations, Haller said. The only treatment right now is surgery. Discovering the condition early would allow us to watch, knowing the potential for serious symptoms is there, and perform that surgery as soon as its necessary.

Sadler B, Wilborn J, Antunes L, Kuensting T, Hale AT, Gannon SR, McCall K, Cruchaga C, Harms M, Voisin N, Reymond A, Cappuccio G, Burnetti-Pierri N, Tartaglia M, Niceta M, Leoni C, Zampino G, Ashley-Koch A, Urbizu A, Garrett ME, Soldano K, Macaya A, Conrad D, Strahle J, Dobbs MB, Turner TN, Shannon CN, Brockmeyer D, Limbrick DD, Gurnett CA, Haller G. Rare and de novo coding variants in chromodomain genes in Chiari I malformation. American Journal of Human Genetics. Dec. 21, 2020. DOI: 10.1016/j.ajhg.2020.12.001

This study was funded by Sam and Betsy Reeves and the Park-Reeves Syringomyelia Research Consortium; the University of Missouri Spinal Cord Injury Research Program; the Childrens Discovery Institute of St. Louis Childrens Hospital and Washington University; the Washington University Institute of Clinical and Translational Sciences, grant number UL1TR000448 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); the Eunice Kennedy Shriver National Institute of Child Health & Human Development, award number U54HD087011 to the Intellectual and Developmental Disabilities Research Center at Washington University; the Swiss National Science Foundation, grant number 31003A_182632; and the Jrme Lejeune Foundation.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

View post:
Common brain malformation traced to its genetic roots - Washington University School of Medicine in St. Louis

Ticas among the 100 Young Leaders of Biotechnology in Latin America – The Costa Rica News

Allbiotech, the organization that promotes the development of biotechnology and the bioeconomy in Latin America, makes a selection each year of the 100 young leaders in that branch of the region.

This 2020 three students from the National University (UNA) of the Biology career and three of the Biotechnology Engineering career of the Technological of Costa Rica (TEC), are part of those selected.

They are Mara Jos Durn, Fiorella Arias and Melissa Cerdas from TEC, and Karol Snchez, Stephanny Snchez and Joyce Estrada from UNA, who with their selection, will have the opportunity to participate in the Leaders Summit 2021.

For Cerdas, being selected as an Allbiotech leader means a whole door of opportunities to revolutionize the Bioeconomy in Latin America. The Summit allows us to unite, identify the challenges of each country and network with many other young people, which allows us to broaden our vision and bring solutions to challenges.

Each was chosen individually for their ability to use science and technology to transform the region. They were selected from more than 500 applicants from across the region. Durn participated in the IGEM 2019 Boston and is currently an intern in a Food Science venture in San Francisco, United States.

Arias was the winner of the 6th Mission Idea Contest and the IAA Award, Tokyo-Japan, and is co-founder of Orbital Space Technologies, a company that seeks to develop the first Central American experiment onboard the International Space Station, to fight against a plague that affects plantations of bananas in Panama. Cerdas is the co-founder of the biotech startup MetLess, which seeks to develop a probiotic to reduce methane emissions in dairy farming.In the case of Karol Snchez and Stephanie Snchez, they are co-founders of the Phase G1 scientific outreach initiative and bacterial study with CRISPR & Cas9. Stephanie has focused on the bioprospecting of new antimicrobials in marine fungi.

Since 2017, 12 Costa Ricans have been selected among the top 100 in Latin America.

Read the original post:
Ticas among the 100 Young Leaders of Biotechnology in Latin America - The Costa Rica News

Is Enlivex Therapeutics Ltd (ENLV) the Top Pick in the Biotechnology Industry? – InvestorsObserver

The 64 rating InvestorsObserver gives to Enlivex Therapeutics Ltd (ENLV) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, ENLVs 64 overall rating means the stock scores better than 64 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Enlivex Therapeutics Ltd (ENLV) stock is trading at $8.32 as of 11:57 AM on Thursday, Dec 31, a loss of -$0.90, or -9.76% from the previous closing price of $9.22. The stock has traded between $8.27 and $9.10 so far today. Volume today is light. So far 125,199 shares have traded compared to average volume of 320,151 shares.

Click Here to get the full Stock Score Report on Enlivex Therapeutics Ltd (ENLV) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is Enlivex Therapeutics Ltd (ENLV) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Matinas BioPharma Holdings Inc (MTNB) the Top Pick in the Biotechnology Industry? – InvestorsObserver

The 71 rating InvestorsObserver gives to Matinas BioPharma Holdings Inc (MTNB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 89 percent of stocks in the Biotechnology industry, MTNBs 71 overall rating means the stock scores better than 71 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 71 means the stock is more attractive than 71 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Matinas BioPharma Holdings Inc (MTNB) stock is trading at $1.41 as of 12:17 PM on Thursday, Dec 31, a drop of -$0.07, or -4.42% from the previous closing price of $1.47. The stock has traded between $1.30 and $1.55 so far today. Volume today is elevated. So far 8,505,458 shares have traded compared to average volume of 4,576,544 shares.

Click Here to get the full Stock Score Report on Matinas BioPharma Holdings Inc (MTNB) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more:
Is Matinas BioPharma Holdings Inc (MTNB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Equillium Inc (EQ) the Top Pick in the Biotechnology Industry? – InvestorsObserver

A rating of 64 puts Equillium Inc (EQ) near the middle of the Biotechnology industry according to InvestorsObserver. Equillium Inc's score of 64 means it scores higher than 64% of stocks in the industry. Equillium Inc also received an overall rating of 54, putting it above 54% of all stocks. Biotechnology is ranked 30 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 54 means the stock is more attractive than 54 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Equillium Inc (EQ) stock is trading at $5.52 as of 10:48 AM on Thursday, Dec 31, a gain of $0.08, or 1.49% from the previous closing price of $5.44. The stock has traded between $5.27 and $5.71 so far today. Volume today is below average. So far 523,209 shares have traded compared to average volume of 947,137 shares.

Click Here to get the full Stock Score Report on Equillium Inc (EQ) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the original post here:
Is Equillium Inc (EQ) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Dicerna Pharmaceuticals Inc (DRNA) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Dicerna Pharmaceuticals Inc (DRNA) is near the top in its industry group according to InvestorsObserver. DRNA gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Dicerna Pharmaceuticals Inc gets a 81 rank in the Biotechnology industry. Biotechnology is number 35 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 63 means the stock is more attractive than 63 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Dicerna Pharmaceuticals Inc (DRNA) stock is trading at $22.69 as of 11:47 AM on Wednesday, Dec 30, an increase of $0.59, or 2.65% from the previous closing price of $22.11. The stock has traded between $22.21 and $23.31 so far today. Volume today is below average. So far 118,827 shares have traded compared to average volume of 652,949 shares.

Click Here to get the full Stock Score Report on Dicerna Pharmaceuticals Inc (DRNA) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See more here:
Is Dicerna Pharmaceuticals Inc (DRNA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Is Mirati Therapeutics Inc (MRTX) the Top Pick in the Biotechnology Industry? – InvestorsObserver

A rating of 82 puts Mirati Therapeutics Inc (MRTX) near the top of the Biotechnology industry according to InvestorsObserver. Mirati Therapeutics Inc's score of 82 means it scores higher than 82% of stocks in the industry. Mirati Therapeutics Inc also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 35 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mirati Therapeutics Inc (MRTX) stock is lower by -0.6% while the S&P 500 is up 0.34% as of 11:44 AM on Wednesday, Dec 30. MRTX is down -$1.32 from the previous closing price of $220.94 on volume of 154,477 shares. Over the past year the S&P 500 has gained 15.75% while MRTX is up 70.43%. MRTX lost -$7.70 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Mirati Therapeutics Inc (MRTX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Is Mirati Therapeutics Inc (MRTX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Should You Buy Spero Therapeutics Inc (SPRO) in Biotechnology Industry? – InvestorsObserver

A rating of 84 puts Spero Therapeutics Inc (SPRO) near the top of the Biotechnology industry according to InvestorsObserver. Spero Therapeutics Inc's score of 84 means it scores higher than 84% of stocks in the industry. Spero Therapeutics Inc also received an overall rating of 68, putting it above 68% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spero Therapeutics Inc (SPRO) stock is lower by -7.34% while the S&P 500 has risen 0.16% as of 10:58 AM on Tuesday, Dec 29. SPRO has fallen -$1.62 from the previous closing price of $22.07 on volume of 181,432 shares. Over the past year the S&P 500 has gained 16.15% while SPRO has risen 109.31%. SPRO lost -$4.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spero Therapeutics Inc (SPRO) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Go here to see the original:
Should You Buy Spero Therapeutics Inc (SPRO) in Biotechnology Industry? - InvestorsObserver

Is Seelos Therapeutics Inc (SEEL) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

The 70 rating InvestorsObserver gives to Seelos Therapeutics Inc (SEEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 89 percent of stocks in the Biotechnology industry, SEELs 70 overall rating means the stock scores better than 70 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Seelos Therapeutics Inc (SEEL) stock is trading at $1.54 as of 11:38 AM on Wednesday, Dec 30, a rise of $0.08, or 5.48% from the previous closing price of $1.46. The stock has traded between $1.41 and $1.60 so far today. Volume today is below average. So far 691,920 shares have traded compared to average volume of 2,118,378 shares.

Click Here to get the full Stock Score Report on Seelos Therapeutics Inc (SEEL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Is Seelos Therapeutics Inc (SEEL) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Is Evofem Biosciences Inc (EVFM) the Top Pick in the Biotechnology Industry? – InvestorsObserver

The 35 rating InvestorsObserver gives to Evofem Biosciences Inc (EVFM) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 27 percent of stocks in the Biotechnology industry, EVFMs 35 overall rating means the stock scores better than 35 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Evofem Biosciences Inc (EVFM) stock is trading at $2.43 as of 9:45 AM on Monday, Dec 28, an increase of $0.07, or 2.97% from the previous closing price of $2.36. The stock has traded between $2.40 and $2.47 so far today. Volume today is light. So far 155,885 shares have traded compared to average volume of 2,741,457 shares.

Click Here to get the full Stock Score Report on Evofem Biosciences Inc (EVFM) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more:
Is Evofem Biosciences Inc (EVFM) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Is Evelo Biosciences Inc (EVLO) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Evelo Biosciences Inc (EVLO) is around the top of the Biotechnology industry according to InvestorsObserver. EVLO received an overall rating of 81, which means that it scores higher than 81 percent of all stocks. Evelo Biosciences Inc also achieved a score of 96 in the Biotechnology industry, putting it above 96 percent of Biotechnology stocks. Biotechnology is ranked 35 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Evelo Biosciences Inc (EVLO) stock is trading at $12.07 as of 11:43 AM on Wednesday, Dec 30, an increase of $0.80, or 7.1% from the previous closing price of $11.27. The stock has traded between $11.35 and $12.39 so far today. Volume today is below average. So far 104,015 shares have traded compared to average volume of 499,735 shares.

Click Here to get the full Stock Score Report on Evelo Biosciences Inc (EVLO) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original here:
Is Evelo Biosciences Inc (EVLO) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Nanoparticles in Biotechnology and Pharmaceuticals Market 2021 Detailed analysis of current Industry trends – NeighborWebSJ

Overview Of Nanoparticles in Biotechnology and Pharmaceuticals Industry 2021-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Nanoparticles in Biotechnology and Pharmaceuticals Market Report a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

The Top key vendors in Nanoparticles in Biotechnology and Pharmaceuticals Market include are:- RocheGE HealthcareMerckNovartisAMAG PharmaceuticalsAmgenBausch & LombBiogenCelgeneGileadIpsenLeadiant BiosciencesnanoComposixPacira PharmaceuticalsPfizerShire

Get a Sample PDF copy of this Nanoparticles in Biotechnology and Pharmaceuticals Market Report @ https://reportsinsights.com/sample/94835

This research report categorizes the global Nanoparticles in Biotechnology and Pharmaceuticals market by top players/brands, region, type and end user. This report also studies the global Nanoparticles in Biotechnology and Pharmaceuticals market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Major Product Types covered are:

FullerenesLiquid CrystalsLiposomesNanoshellsQuantum dotsSuperparamagnetic nanoparticles

Major Applications of Nanoparticles in Biotechnology and Pharmaceuticals covered are:

Region wise performance of the Nanoparticles in Biotechnology and Pharmaceuticals industry

This report studies the global Nanoparticles in Biotechnology and Pharmaceuticals market status and forecast, categorizes the global Cable Conduits market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

To get this report at a profitable rate.: https://reportsinsights.com/discount/94835

The study objectives of this report are:

Scope of the Report:-

The report scope combines a detailed research of Global Nanoparticles in Biotechnology and Pharmaceuticals Market 2021 with the apprehension given in the advancement of the industry in certain regions.

The Top Companies Report is designed to contribute our buyers with a snapshot of the industrys most influential players. Besides, information on the performance of different companies, profit, gross margin, strategic initiative and more are presented through various resources such as tables, charts, and info graphic.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market-2020-94835

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

https://neighborwebsj.com/

View original post here:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2021 Detailed analysis of current Industry trends - NeighborWebSJ

Animal Biotechnology Regulatory Framework Being Transferred to USDA – AG INFORMATION NETWORK OF THE WEST – AGInfo Ag Information Network Of The West

U.S. Secretary of Agriculture Sonny Perdue announced a significant step in modernizing regulations of agricultural animals modified or produced by genetic engineering.

The U.S. Department of Agriculture (USDA) will be moving forward with an Advanced Notice of Proposed Rulemaking (ANPR) to solicit public input and feedback on a contemplated regulatory framework that would modernize our system into a scientifically-sound, risk-based, and predictable process that facilitates the development and use of these technologies for U.S. farmers and ranchers under USDA's authorities.

This initiative follows President Donald Trump's Executive Order on agricultural biotechnology that called upon federal agencies to make regulatory improvements to rectify some of the long-standing barriers to innovation for U.S. agriculture.

"Our livestock producers need all the tools in the toolbox to help protect against animal diseases and continue to meet the challenge of feeding everyone now and into the future.

"If we do not put these safe biotechnology advances to work here at home, our competitors in other nations will," said Secretary Perdue.

"Science-based advances in biotechnology have great promise to continue to enhance rural prosperity and improve the quality of life across America's heartland and around the globe.

"With this effort, we are outlining a pragmatic, science-based, and risk-based approach that focuses on potential risk to animal and livestock health, the environment, and food safety in order to provide our farmers and ranchers the tools they need to continue to feed, clothe and fuel the world."

Source: USAgNet

Go here to see the original:
Animal Biotechnology Regulatory Framework Being Transferred to USDA - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Where Does Sangamo Therapeutics Inc (SGMO) Stock Fall in the Biotechnology Field? – InvestorsObserver

A rating of 85 puts Sangamo Therapeutics Inc (SGMO) near the top of the Biotechnology industry according to InvestorsObserver. Sangamo Therapeutics Inc's score of 85 means it scores higher than 85% of stocks in the industry. Sangamo Therapeutics Inc also received an overall rating of 68, putting it above 68% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Sangamo Therapeutics Inc (SGMO) stock has fallen -5.99% while the S&P 500 has risen 0.16% as of 10:58 AM on Tuesday, Dec 29. SGMO is lower by -$1.08 from the previous closing price of $18.04 on volume of 1,307,640 shares. Over the past year the S&P 500 has risen 16.15% while SGMO has risen 108.10%. SGMO lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Sangamo Therapeutics Inc (SGMO) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Continued here:
Where Does Sangamo Therapeutics Inc (SGMO) Stock Fall in the Biotechnology Field? - InvestorsObserver

8 of the Best Inflammation-Fighting Tips We Learned All Year – Well+Good

If youre a regular Well+Good reader, you know inflammation is something we ask medical doctors and experts about a lot. New here? Inflammation is the bodys natural process of fighting against things that harm it, such as infections, illnesses, injuries, and toxins in an attempt to heal itself. Inflammation isnt inherently a bad thingbut when it becomes chronic, it can lead to health conditions as diverse as acne, cancer, and cognitive decline.

Its because chronic inflammation is the root cause of nearly all health woes that we ask experts about it so often. And in the process, weve learned a lot. So were sharing the knowledge with you, dear reader, so you can act on this life-promoting advice. Rounded up here are 10 of the best inflammation-fighting tips we learned this year. Each tip links to full articles, just in case you want to do a deeper dive.

Does your morning cup of coffee protect against inflammation? Doctors tell us that the answer is complicated. Some studies connect caffeine to protecting against chronic health conditions, but how quickly you metabolize caffeine and underlying health conditions also matter. The source matters too. For example, some caffeinated teas, like green or black, are widely accepted by the scientific community to reduce inflammation, but an energy drink cant boast the same.

Read more: Does Caffeine Cause Inflammation? Its Complicated

Theres a popular belief in the wellness world that dairy is a highly inflammatory food group, but the truth is less cut and dry. Experts tell us (and scientific studies show) that dairy only causes inflammation in those with an allergy or intolerance.

Read more: Does Dairy Really Cause Inflammation? Its Complicated

Fighting inflammation extends beyond food. Making a habit of meditating just 10 minutes daily has been shown to reduce inflammation in the body. This is because it helps lower cortisol levels (aka the stress hormone), which plays a regulatory role in the immune system. When cortisol levels remain at high levels, it can causeyou guessed it, inflammation.

Read more: The 10-Minute Wellness Habit That Fights Inflammation

Another way to protect the body from inflammation that doesnt have to do with food is by exercising regularly, and it really doesnt take super long workouts to get the benefits. A preventive medicine doctor tells us that just 20 to 30 minutes a few times a week is enough to make an impact.

Read more: Does Exercise Reduce Inflammation? Heres What a Preventive Medicine Doc Says

Theres a lot of herbs in your pantry that are linked to lowering inflammation, but cinnamon is one that tends to be overlooked. Its high antioxidant content is especially good for your heart. Who says you have to choose between something sweet and something anti-inflammatory?

Read more: 5 Cinnamon Drinks That Work As a Delicious Way To Combat Inflammation

When we heard about a nutritional epidemiologist who created an inflammation index of the most popular foods, we had to call her up to learn more. Spoiler: leafy greens, tomatoes, apples and berries, deep yellow or orange vegetables, nuts, legumes, and fish are all linked to lowering the risk for inflammation. Added sugar, on the other hand, has one of the highest inflammation scores.

Read more: This New Inflammation Index Shows Just How Healthy Your Favorite Foods Are

While, yes, turmeric is powerfully linked to lowering inflammation, its certainly not the end all be all. In the video above, a registered dietitian shares other foods worth working into your diet including berries, Brussels sprouts, and mushrooms. And if youre looking for another supplement to try, consider the plant compound quercetin, which is anti-inflammatory and linked to potential anti-aging benefits.

Read more: The Underrated Anti-Inflammatory Nutrient That Will Help You Live Longer, According to a Functional Medicine Doctor

Sore muscles are a sign of acute inflammation. In the short-term, this is NBD, but left untreated, its bad news for your body. This is exactly why workout recovery matters. Moderate exercise is great for warding off chronic inflammation, but if you go hard on a regular basis, your body needs a little love too.

Read more: 8 Ways To Use Your Workout and Recovery Routine To Reduce Inflammation

Oh hi! You look like someone who loves free workouts, discounts for cult-fave wellness brands, and exclusive Well+Good content. Sign up for Well+, our online community of wellness insiders, and unlock your rewards instantly.

See more here:
8 of the Best Inflammation-Fighting Tips We Learned All Year - Well+Good

2020, COVID-19 and Reflection on Human Immortality Tunji Olaopa – THISDAY Newspapers

The year 2020 will go down in history as the annus horribilis for the human race; the year that millions of lives were forfeited to a tiny and inanimate virus with no sensate hope or ambition. Yet, the coronavirus has decimated millions, and left many millions more cowering in our helplessness. This is one terrible year when most humans, for whom death is often a distant thought, came face to face with the possibility of a sudden demise from a COVID-19 ambush. 2020 has been the very definition of uncertainty for everyone, from the mighty to the lowly. We all got sucked into the vortex palpable fearno one knew when the virus will strike, where it could be contracted, or how fatal it could be. COVID-19 became the most lethal of all the enemies humans have ever contended with. And it fueled our uncertainty in the very fact that we had no certain fact about its character and modus operandi.

As the usual tradition goes with the coming of a new year, we all welcomed 2020 with hope and resolutions. Governments made budgets, humans made plans, organizations made projections. The year was to be the usual in the trajectory of human activities and busyness. Children will be born, and adult will grow old and die. There will be achievements all around the world, and calamities too. The usual diseases will keep ravaging humanity, from cancer to tuberculosis. All the states of the world would battle their normal internal crises and predicament, and few resolutions would be made. And yet, we all neglected what had been on humanitys radar since humanity began its civilizational march many centuries ago; the very underbelly of humans desire to transcend themselves.

COVID-19 brought humanity very low. It humbled us at the very height of our civilizational achievements. Ralph Waldo Emerson, the American philosopher, once perceptively remarked: The end of the human race will be that it will eventually die of civilization. Since the Stone Age, and then the Industrial Revolution, humanity has grown beyond its cradle which is the earth. We not only concretized the fragility of the earth; we also have turned our attention to the space. Humanity has arrived at what Mark Twain called the limitless multiplication of unnecessary necessities. This validates the Yoruba adage that when humans have eaten and are surfeited, they then look for unnecessary distractions.

After civilization had settled the issue of survival, it was then time for humans to transcend themselves, especially through the discoveries of science and technology and its limitless possibilities and dangers in ways that are often indistinguishable. When humans cracked the secret of the atom, we arrived at the nuclear reactor as well as the nuclear atomic bomb. We now contemplate a posthuman world with the breakthrough with artificial intelligence.

In its very essence, civilization commenced as humanitys search for survival. It has now been transformed into an exploration of our possible immortality. To be human is not only to be mortal, but to also have the capacity to perceive the infinite, which we do not see in our finitude. Humanity is trapped in the yearning for infinitude; the desire to undermine our mortality and live forever. Abraham Lincoln puts it better: Surely God would not have created such a being as man, with an ability to grasp the infinite, to exist only for a day! No, no, man was made for immortality. And so, once the first land was tilled and farmed, agriculture enabled humans to conquer starvation. But it also enabled an abundance that helped us to keep staving off death. With medicine, humans started to invade the genetic code to hold off the principle of ageing encoded into our being. We started battling diseases and sicknesses, and also death. Immortality therefore lies in the achievement of civilization for humanity. We have to keep overreaching ourselves in other to be able to overreach our mortality.

Unfortunately, civilization is what makes you sick, says Paul Gauguin, the French post-impressionist artist. But more than this, civilization already puts in stock the pointer to what will eradicate humanitythe nuclear threat, and the virus. Since the combined effort of humanitys brilliant scientists unlocked the secret of the atom, the human race has remained on the precipice of self-destruction. When Hiroshima and Nagasaki snowballed into the atomic mushroom, we saw in that catastrophe, the possibility of undermining our own race for immortality. That is the paradox of civilization: it contained the seed for our immortality and our destruction in unequal proportion. In other words, we are more likely to be destroyed than to achieve immortality. If humanity is destroyed, then there will be no one left to remember us. This is where the insight of Emerson leads usthe civilization we have invented to ensure our immortality is what will most likely kill and efface us and all the infinitude we ever hoped for.

The reality of our accelerated mortality came alive in 2020. Nature rebelled against the unmitigated assault on her sanctity and exploitation. A family of the coronaviruses jumped its boundary and landed in the civilized space of humanity. And we were not prepared because we have always underestimated the virus. After all, we seem to have got the structure of most of the viruses we know and their epidemiological features. The common cold is one of the most dangerous ailment afflicting humanity, but we seem to have tamed it. What can we not tame? Yet, we have arrived at the limit of human hubris. And it is neither yet from aliens in outer spaces nor from artificial intelligence. It is from a lowly virus that is inorganic and inanimate. There is less we know about the virus and its behavior than we really know. The novelty of the coronavirus effectively undermines the accumulated scientific knowledge about its type that we have stockpiled for decades.

Mercifully, 2020 has also become the year in which humanity has managed to get an understanding of the vaccination that will stop the virus in its deadly track. Of course, human beings have the resilience to always overcome whatever adversity is brought on them either naturally or by their own efforts. But then, humanity has brought itself too many times to the precipice of destruction not to take notice of the dangerous side of our existence and the search for immortality. Essentially, it is human hubris that brought the pandemic of 2020 upon us. It is our inability to take stock of our civilizational progress and how far we are willing to go to transcend our humanity. It is certain that the Pfizer/BioNTech vaccines, for instance, and all the others almost ready for us will provide instant relief from the scourge of the COVID-19. But should the fact of the vaccines, or human resilience in the face of troubles, blind us to how far-fetched our search for immortality is, or how dangerous?

Hippocrates, the ancient Greek physician, has a piece of wisdom we can draw on: A wise man should consider that health is the greatest of human blessings, and learn how by his own thought to derive benefit from his illnesses. What insight do we need to urgently derive from this pandemic, and from others that have afflicted humankind? What deep lessons does COVID-19 teach us in 2020? It is simple: there is a need to de-escalate humanitys rush for self-destruction. If this family of coronavirus could make the fatal jump into the human host, there are so many more that can. Thus, the arrival of the breakthrough in vaccination against the coronavirus ought not be interpreted as the resumption of our human normality or the onslaught against nature. On the contrary, it ought to be a time to pause and reassess what it means to be human, and what civilization ought to mean.

And more than this, we need a redefinition of what it means to be immortal. Humans can only be immortal in the face of posterity and the state in which we leave the world. Posterity is our immortality. Unfortunately, the logic of civilization is often oriented towards a further exploitation of the universe with scant thought for what future generations will make of the progress we have achieved, and the failures we leave behind. It ought to be clear to humanity now that civilization is amok.

From the First to the Fourth Industrial Revolution, humans are barely managing the benefits of progress since we are ever confronted with the threat of imploding the world as we know it. 2020 and the pandemic make it very clear to us that we are nearer destruction, and the undermining of our own immortality, that we imagine. The COVID-19, uncontained, has the capacity to kill the whole of humanity. And we have barely even managed to get it arrested. And who knows what the future of more scientific and technological breakthrough holds? The coronavirus is insisting on the imperatives of weighing human progress on the scale of morality. Civilizational progress is not an unconditional good. It needs to be tempered by further thought on how our immortality can be retained in the womb of the future of those yet unborn.

Prof. Tunji Olaopa, Retired Federal Permanent Secretary & Directing Staff, National Institute for Policy and Strategic Studies (NIPSS), Kuru, Jos, tolaopa2003@gmail.com, tolaopa@isgpp.com.ng.

Like Loading...

View original post here:
2020, COVID-19 and Reflection on Human Immortality Tunji Olaopa - THISDAY Newspapers

Keanu Reeves addresses rumours of him being immortal, jokes with Fallon in an interview – Republic World

Keanu Reeves isfamousnot just for his acting skills and hit movies but his timeless John Wick hairstyle which has been popular since the film's first installment. Keanu Reeves fans argue that it isn't just his hairstyle that is timeless but fans think the actor seems to never age, some even suggest that the actor is immortal, in what has become a running trope. During one of his interviews when he was confronted about this, he expertly dodged the nonsensical non-seriousclaims. Read all the details about this interview here.

ALSO READ:'John Wick 2' Cast: Know The Actors Who Starred In This Keanu Reeves' Action Thriller Film

During an interview with Jimmy Fallon on The Tonight Show Starring Jimmy Fallon in 2017, the presenter of the show asked Keanu Reeves about the immortality claims by the fans. He confronted the actor with some pictures from the fan site Keanuisimmortal.com. He showed him a series of photographs which show that the actor looks similar to some of the historic figures shown. While the actor agreed that there are some similarities between all these personalities he neither accepted nor denied the claims made.

Reeves and Fallon both joked about the notion and theories of how Keanu could actually be immortal and has been alive for centuries. Although these jokes acknowledge the similarities it doesn't cancel the potential immortality theory. These jokes still seem like an expert dodge and another bit towards a confirmation according to some conspiracy theorists.

ALSO READ:Keanu Reeves Sports A Buzzcut, Chops Off Famous Long Locks For Upcoming Movie

ALSO READ:Cyberpunk 2077 Mix It Up Poster: Learn About The Controversial Ad In The Game

Keanu Reeves is not active on social media. The actor keeps a very low profile and doesn't share a lot of personal updates on the internet. Even after all his attempts to not be very social, the actor's fans have made him a social media superhero. According to the reports by Showbiz Cheat Sheet Reeves' acts of generosity and philanthropy have established the actor in everyone's good books. In 2019 when he went public about his relationship with his girlfriend Alexandra Grant the internet fanseven titled him asthe internet's boyfriend.

While there have been many memes surrounding the actor, many claims were made about his immortality and ageless looks. Fans have noted similarities between Keanu Reeves and many other historical figures such as Vlad the Impaler, artist Parmigianino and actor Paul Mounet. The 56-year-old actor resembles these popular figures who lived centuries apart.

ALSO READ:Keanu Reeves To Feature In Tom Cruise's Next Mission Impossible Film?

Get the latest entertainment news from India & around the world. Now follow your favourite television celebs and telly updates. Republic World is your one-stop destination for trending Bollywood news. Tune in today to stay updated with all the latest news and headlines from the world of entertainment.

Read more:
Keanu Reeves addresses rumours of him being immortal, jokes with Fallon in an interview - Republic World

Recognizing Hall of Famer Paul Westphal – Suns.com

Hey, now youre immortal, Paul Westphal said in relating what someone told him when they learned he was going to be inducted into the Basketball Hall of Fame.

No, Westphal said during his induction speech in September 2019, responding to the well-wisher, immortality doesnt come from basketball.

As we pause to remember Westphal, and share how saddened we are at his passing, we recognize how prophetically spot-on he was.

Westy will not be immortalized for just playing basketball. He will be remembered for how he lived his life, and how he treated others.

The Phoenix Suns organization shares its thoughts and prayers with the Westphal family through this difficult time.

Westy will forever be remembered as a prominent Valley sports legend both on and off the court, said Suns Managing Partner Robert Sarver. He built an illustrious career as both a player and a coach. His legacy ranks among the most quintessential basketball icons of all time.

Westphal left an indelible signature on the Phoenix Suns franchise with his All-NBA talent, his brilliant mind and his elite character. From guiding the team on the court in the 1976 NBA Finals to leading them from the sidelines in the 1993 NBA Finals, Westphals legacy in Phoenix crossed decades and his overall impact on the organization is virtually unmatched.

Throughout the past 40 years, Westy has remained a great friend of the organization and as a trusted sounding board and confidant for me, Sarver continued. His number 44 will forever hold its place in our Ring of Honor, enshrined as one of the utmost deserving members.

Born on November 30, 1950, Westphal was a native of Torrance, CA, and spent 14 seasons with the Suns as a player and a coach.

The eventual Basketball Hall of Famer known as Westy was acquired by the Suns in a trade with the Boston Celtics in 1975 and spent six seasons as a player with Phoenix. He ultimately found his way back in the Valley a few years later on the Suns coaching staff from 1988-95. Due to his astounding career and impact across the NBA, Westphal was enshrined in the Naismith Memorial Basketball Hall of Fame on September 6, 2019.

There may be just a handful of people who have as much influence and significance on the history of the Phoenix Suns, Jerry Colangelo said. All he accomplished as a player and as a coach. Off the court, he was a gentleman, a family man, great moral character. He represented the Suns the way you want every player to represent your franchise.

Known for his high basketball IQ, Westphal was instrumental in leading the Suns to their first NBA Finals appearance in 1976 against the Celtics. This series featured The Greatest Game Ever Played a triple-overtime thriller during which Westphals quick thinking helped put the Suns in position to extend the game behind Garfield Heards famous Shot Heard Round the World.

He was cerebral in his game, Colangelo said. He was always thinking one step ahead. Even the infamous triple-overtime game in Boston during the Final series, when he was the one who said, 'Call the timeout.' which forced a free throw, but gave us the ball at halfcourt and set up the opportunity to tie the game, which we did. That's thinking right on the spot at the moment.

Westphal became a five-time All-Star (four with the Suns) and garnered All-NBA recognition for four consecutive seasons, including three selections to the First Team. He sits as the eighth-leading scorer in Suns history, totaling 9,564 points and averaging 20.6 points per game, and was inducted into the Suns Ring of Honor on April 15, 1989.

Westphal joined the coaching ranks upon retirement and came back to the Suns as an assistant in 1988. Once back with the organization, Westphal learned under fellow Suns Ring of Honor member Cotton Fitzsimmons as he brought his basketball intelligence to the sidelines. Even as an assistant coach, Westphal proved his worth and garnered credit for his player relationships and development skills, including that of 1989 Sixth Man of the Year Eddie Johnson.

He led by example, Johnson said. He didn't change off of the court. It's just a positive atmosphere that he exudes when he's around. He always greets you with a pleasant smile. You always feel like you are a part of his clique. He's somebody we can put on a pedestal.

Westphal spent four seasons in this role under Fitzsimmons before taking over as head coach for the 1992-93 season. His success came early and often, leading the Suns to the best record in the league and a trip back to the NBA Finals in his first season at the helm. During his time as head coach in Phoenix, Westphal amassed a record of 191-88, which ranks as the fourth-most wins of any head coach in team history while his .685 winning percentage is best in Suns coaching history.

We had a personal relationship that spans decades, Colangelo said. He played for me. He coached for me. I always had great respect for Paul and he added to the quality of my life just with his presence. I'm very thankful that I had the opportunity to be associated with him."

Westphal left an everlasting legacy on the Suns franchise and within the city of Phoenix. While his greatest accomplishments may have come in the Valley of the Sun, his ultimate impact on basketball stretches from a young high school star in Southern California through a storied career as player, coach and broadcaster.

Westphal attended Aviation High School in Redondo Beach, Calif., where he was named the 1968 California Interscholastic Federation Player of the Year as a senior. He attended USC and earned All-Pac 8 honors in all three seasons with the Trojans. USC retired Westphals number 25 jersey and he was inducted into their Athletic Hall of Fame in 1997.

Westphal was drafted 10th overall in the 1972 NBA Draft by the Boston Celtics where he spent the first three years of his career, including the Celtics 1974 championship season. He was traded to Phoenix for future Basketball Hall of Famer Charlie Scott on May 23, 1975. He also first left the Suns in exchange for a future Basketball Hall of Famer, Dennis Johnson, on June 4, 1980.

He played one season with the Seattle SuperSonics and two seasons with the New York Knicks, winning Comeback Player of the Year for the Knicks in 1982-83. He returned to Phoenix for the final season of his 12-year playing career in 1983-84.

Westphal began his coaching career in 1985 with Southwestern Baptist Bible College (now Arizona Christian University). After finishing the season 3-20 the year before, he guided them to a 21-9 record in his lone season. He was then hired as the head coach of Grand Canyon University, leading them to a 63-18 record over his two seasons, including a NAIA National Championship in 1988.

In addition to four season as Head Coach of the Suns, Westphal spent three seasons as head coach of the Seattle SuperSonics, five seasons as head coach of Pepperdine University, one season as an assistant coach for the Dallas Mavericks, three seasons as head coach of the Sacramento Kings, and finished his coaching career with two seasons as an assistant coach for the Brooklyn Nets.

Westphal is survived by his wife Cindy, and his son Michael and daughter Victoria.

Thank you, Paul. Rest in Peace.

More:
Recognizing Hall of Famer Paul Westphal - Suns.com

How are former Yankees doing in the Hall of Fame voting? – Empire Sports Media

The voting process for the National Baseball Hall of Fame, Class of 2021, ended on December 31. The ballot has 25 candidates in total, and eight of them spent at least part of their career with the New York Yankees.

Bobby Abreu, A.J. Burnett, LaTroy Hawkins, Nick Swisher, Roger Clemens, Andruw Jones, Andy Pettitte, and Gary Sheffield are among the Yankees that are eligible for immortality.

However, as of right now with 115 ballots published, no one is making the cut to get in. Players in the ballot need to get a minimum of 75% of the votes to gain immortality. So far, Clemens (72.2%) is the closest of the former Yankees, with Barry Bonds and Curt Schilling also flirting with the minimum threshold.

The results will be announced on January 26, and the inductees will be honored in Cooperstown, New York, on July 25, barring any COVID-19-related postponement.

So far, here are the former Yankees and their progress through 115 votes, per NJ Advance Media:

Four first-time candidates were elected to the Hall in the last three years: Chipper Jones and Jim Thome in 2018, and former Yankees legends Mariano Rivera in 2019 (unanimous election), and Derek Jeter in 2020.

Jeters case was notorious, as he fell just one vote short of being the second unanimous election to the Hall after his friend and former teammate Rivera.

Abreu appears destined to get the minimum votes to see his name on the ballot for next year (5%), but Burnett, Hawkins, and Swisher, so far, look as one-and-done candidates.

More:
How are former Yankees doing in the Hall of Fame voting? - Empire Sports Media

Tomase: There’s no defending voting for 10 Hall of Famers this year – NBC Sports Boston

At the risk of denigrating the accomplishments of this year's nominees, it's hard to recall a weaker Hall of Fame ballot.

Of course Barry Bonds and Roger Clemens deserve enshrinement, depending on your tolerance for their truthfulness before Congress, but their case stopped being argued on its merits a long time ago.

I'll always consider Curt Schilling a slam-dunk choice for his postseason exploits alone, but I can see why others disagree, and frankly, in light of the comically toxic disinformation that spews from his feeds in a Deepwater Horizon-style geyser, I don't mind seeing him twist in the wind, because I am incredibly petty.

The fourth and final name on my ballot, Gary Sheffield, receives even less support, but I happen to believe he's one of the 30 greatest hitters ever, and if we won't reward that just because he plodded across the outfield like a hastily recommissioned Soviet Era tank, then what are we doing?

So we can quibble about this candidate or that, but here's what I can't countenance: examining this ballot and deciding that eight, nine, even 10 names belong in Cooperstown.

It is time to stage a BBWAA-wide intervention.

Over the last seven years, a record 22 players have earned enshrinement from the writers, finally breaking the PED backlog that basically coincided with the arrivals of Bonds and Clemens.

The 2021 ballot includes 25 names and if you pick 10 of them, that means you believe 40 percent of the qualifiers deserve immortality. That's not exactly an Ivy League acceptance rate, and we're supposed to be honoring the absolute best of the best.So what's going on?

Chalk it up to a pair of developments ruining our lives in different ways -- social media and the statistical revolution.

The former speaks for itself. Loudly. And not always with real people supplying the words.

Though the One True Ballot police have thankfully lowered their weapons since the overheated heyday of 2014, there's still an element of the voting populace that would rather satisfy Twitter banshees than defend leaving someone else's favorite player off their ballot. Easier to just check the maximum and then back away slowly with hands raised. "I would've voted for your guy, but the limit is 10. Can I go now? I have a wife and family."

I believe it was the great Ray Ratto who boiled this conflict down to, "I want a vote / you can't have one." The armchair experts -- whose theoretical ballots look suspiciously homogenous, by the way -- believe that their choices are The Way with the fervency of a Mandalorian. And if you disagree, it's to be expected, because that what happens when you entrust the vote to a group cursed with such breathtaking collective ignorance.

So where do they derive their preternatural confidence? Statistics, of course. The rise of analysts like Jay Jaffe of Fangraphs has given voters new ways to consider the ballot. Jaffe's case for Sheffield, for instance, helped clarify my own stance on his candidacy. (As an aside, I'm just not holding defensive metrics against someone who played the majority of his career before that data was even tracked accurately).

The larger point that's missed when considering his work, and others like it, is that it's not presented as definitive. Jaffe makes a case. His JAWS metric provides context for how a candidate's peak seasons compare to the average Hall of Famer's.

It's not meant to be absolutist, but it's often interpreted that way. When the Hall of Fame becomes an actuarial exercise of sorting career WAR and JAWS in descending order, and go bleep yourself if you even consider subjective measures like MVP votes or All-Star games or postseason dominance or hell, how watching Sheffield swing his bat like a cornered antihero made you feel, then we've lost our way in a style befitting today's broken game, where a Cy Young winner can get lifted in Game 6 of a World Series shutout after only two hits and 73 pitches, because that's what the numbers say.

The numbers also say that Bobby Abreu is a Hall of Famer. They say the same thing about Todd Helton and Andruw Jones and Scott Rolen and Billy Wagner.

They were all very good players. Rolen probably borders on great. But I'll again ask: what are we doing? Are we granting every above-average player immortality? Or are we holding the Hall of Fame to a higher standard than enshrining four out of every 10 nominees?

I know where I fall, which is why I'm comfortable submitting a ballot with four names total. Feel free to @ me. I will definitely ignore you.

See the original post:
Tomase: There's no defending voting for 10 Hall of Famers this year - NBC Sports Boston